Drug intelligence / Profile preview

PTx808

Development stage: Preclinical
Lead developer: Primal Therapies
Modality: Small Molecules
Administration: Topical

Overview

PTx808 is a preclinical-stage small molecule therapeutic being developed by Primal Therapies for daily oral care. It utilizes the company's proprietary SMMRT (Selective Microbial Metabolism Regulation Technology) to selectively regulate oral microbial metabolism. The drug acts as a prebiotic, postbiotic, and antimicrobial agent, aiming to maintain a healthy oral microbiome by targeting specific metabolic pathways of oral bacteria rather than broad-spectrum elimination. It is currently in discovery and formulation development phases.

Beyond the preview

Go deeper on PTx808.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTx808.

Explore the full profile